now under the leadership of a former genentech veteran.ding to a person close to the company, this round of a valuation of $1.1 billion. joining me now from mountain view for an exclusive interview, andy page, president of 23 and me. andy thank you for joining us. , a lot has changed since you and the fda had a bit of a standoff over what 23 and me should and should not be doing. so tell me what does 23 and me , do today and what will it do in the future? how does this change your vision for the company? andy: post fda warning letter, we no longer sold our health reports in the united states. we will be relaunching imminently our status reports. but really a whole new customer experience. the entire site has been redeveloped and redesigned. so it's a very exciting development for the company. emily: if i customer, what can i get if i come to you? if it's not a dna test or an ancestry test, what will i get? andy: if you were to come today, you would receive ancestry. if you were to come after we launch, you would get ancestry, but also trai